1 's Health Insurance Program (CHIP) coverage (
intent-to-treat analyses).
2 s maintenance fluids for 48 hours or longer (
intent-to-treat analyses).
3 111 placebo) in VISUAL-2 were studied using
intent-to-treat analyses.
4 cts were randomized, with 24 included in the
intent-to-treat analyses.
5 ttreatment assessments, and were included in
intent-to-treat analyses.
6 Data were analyzed using
intent-to-treat analyses.
7 This effect was not observed in the
intent-to-treat analyses.
8 an immunodeficiency virus (HIV) infection in
intent-to-treat analyses.
9 Data were analyzed by
intent-to-treat analyses.
10 nts were randomly assigned and considered in
intent-to-treat analyses (
103 patients in arm A and 101
11 In
intent-to-treat analyses,
12 (19%) assigned to treatment
12 In modified
intent-to-treat analyses,
172 of 216 (80%; 95% confidenc
13 In the
intent-to-treat analyses,
178 (11.5%) of 1547 patients r
14 Intent-to-treat analyses and comparisons based on actual
15 er they attended any treatment sessions (ie,
intent-to-treat analyses),
and no covariates still showe
16 In
intent-to-treat analyses at 26 weeks, the percentage of
17 ciated with lower MSI scores at follow-up in
intent-to-treat analyses compared with WLC plus treatmen
18 Using linear mixed-effects models, in
intent-to-treat analyses,
cortisol slopes were maintaine
19 Primary, mixed model,
intent-to-treat analyses covaried for six genetic varian
20 Intent-to-treat analyses demonstrated substantial improv
21 Intent-to-treat analyses demonstrated that AFPT improved
22 Intent-to-treat analyses demonstrated that the intervent
23 In
intent-to-treat analyses,
estrogen plus progestin increa
24 In covariate-adjusted
intent-to-treat analyses,
haloperidol was associated wit
25 In
intent-to-treat analyses,
HSV shedding was detected in 2
26 Intent-to-treat analyses indicate that PE is effective i
27 Secondary analyses included the
intent-to-treat analyses of death or MI composite at day
28 In
intent-to-treat analyses,
patients treated with sertrali
29 ion, lack of reporting of power, and lack of
intent-to-treat analyses remain common.
30 Intent-to-treat analyses revealed that intervention part
31 Intent-to-treat analyses showed a fluoride varnish prote
32 Intent-to-treat analyses showed that patients in both gr
33 Intent-to-treat analyses showed that the intervention, c
34 Intent-to-treat analyses showed that the Lifestyle+LV gr
35 Intent-to-treat analyses showed the behavioral e-counsel
36 In modified
intent-to-treat analyses that excluded women with miscar
37 In
intent-to-treat analyses the FACI-only group had an incr
38 For
intent-to-treat analyses,
the date a parent was selected
39 Using
intent-to-treat analyses,
there was no significant effec
40 We did mixed-effects,
intent-to-treat analyses to examine treatment effects on
41 In
intent-to-treat analyses,
we used linear mixed-effects m
42 Intent-to-treat analyses were conducted using all follow
43 Intent-to-treat analyses were done for disease-free surv
44 Intent-to-treat analyses were performed February 28, 201
45 Intent-to-treat analyses were performed using analysis o
46 neration, allocation concealment, power, and
intent-to-treat analyses were persistently low.
47 ence generation, allocation concealment, and
intent-to-treat analyses were present even in the high-i
48 While
intent-to-treat analyses yield null results, this explor
49 Intent-to-treat analyses yielded similar results.